Results 181 to 190 of about 71,439 (210)

Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study

Cancer Cell, 2021
Chongrui Xu, Ying Cheng, Jiu-Wei Cui
exaly  

Click ferrocenyl-erlotinib conjugates active against erlotinib-resistant non-small cell lung cancer cells in vitro

Bioorganic Chemistry, 2022
Przemysław Biegański, Chiara Riganti, Daniel Fábio Kawano   +2 more
exaly  

Erlotinib

Reactions Weekly, 2017
openaire   +2 more sources

Erlotinib

Reactions Weekly, 2008
  +5 more sources

Erlotinib

Reactions Weekly, 2007
openaire   +1 more source

Erlotinib

Reactions Weekly, 2006
openaire   +1 more source

2-Methoxyestradiol synergizes with Erlotinib to suppress hepatocellular carcinoma by disrupting the PLAGL2-EGFR-HIF-1/2α signaling loop

Pharmacological Research, 2021
zheng shufang, Yong Yang
exaly  

Erlotinib

Reactions Weekly, 2015
openaire   +2 more sources

Angiogenin/Ribonuclease 5 Is an EGFR Ligand and a Serum Biomarker for Erlotinib Sensitivity in Pancreatic Cancer

Cancer Cell, 2018
Ying-Nai Wang, Heng-Huan Lee, Chao-Kai Chou   +2 more
exaly  

Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer

Annals of Oncology, 2015
Igor N Bondarenko, Fiona H Blackhall
exaly